TrialESMO open2022

Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma.

S Canova et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.